演題詳細

ポスター / Poster

ポスター 26 (Poster 26) :B細胞性リンパ腫:Chemotherapy

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
塚本 憲史 (Norifumi Tsukamoto):1
1:群馬大学医学部附属病院 腫瘍センター
 
前へ戻る

Efficacy of 90Y-ibritumomab tiuxetan in low grade B-cell lymphoma

演題番号 : PS-1-195

渡邊 祐子 (Yuko Watanabe):1、野坂 生郷 (Kisato Nosaka):1、白石 慎哉 (Shinya Shiraishi):2、奥野 豊 (Yutaka Okuno):3、麻生 範雄 (Norio Asou):3、満屋 裕明 (Hiroaki Mitsuya):3

1:Cancer Center, Kumamoto University Hospital, Japan、2:Department of Radiology, Kumamoto University Hospital, Japan、3:Department of Hematology, Kumamoto University Hospital, Japan

 

[Intrduction] 90Y-ibritumomab tiuxetan, which is a anti-CD20 monoclonal antibody-based radio-immunologic drug with 90Y, has been used for the treatment of CD20-positive low-grade B cell lymphoma. We examined clinical outcomes of 17 patients treated with 90Y-ibritumomab tiuxetan therapies in our hospital.[Patients and methods] From December 2009 to December 2012, 17 patients (10 men and 7 women) were treated with 90Y-ibritumomab-tiuxetan. 15 patients had follicular lymphoma (FL) and two had mantle cell lymphoma. As grouped with FLIPI score, there were low, intermediate and high-risk groups with 4, 3 and 8 cases of FL, respectively. Before 90Y-ibritumomab tiuxetan adminisitration, the numbers of preceding therapies administered were 1 for 5 cases, 2 for 4 cases, and >4 for 9 cases. [Results] The overall response rate was 76% (CR: n=8, PR: n=5, SD: n=3, PD: n=1). Median progression free survival period was 493 days (range 148-926 days). Among four patients, who had >1000 U/L of serum sIL-2R levels before 90Y-ibritumomab therapy, two had SD and one had early relapse. PET/CT was performed for 8 patients with FL before and after treatment, and the values of the SUV max of tumors in all the 8 cases, plus the 3 SD cases, were decreased.[Conclusions] 90Y ibritumomab therapy showed a high response rate as a salvage therapy for refractory and relapsed indolent B-cell lymphomas. However, patients with the high tumor burdens and high serum levels of sIL-2R may need to be treated with more effective and long-acting regimens, which are to be further developed.

前へ戻る